Activity of Isoliensinine in Improving the Symptoms of Type 2 Diabetic Mice via Activation of AMP-Activated Kinase and Regulation of PPARγ

• DOI: 10.1021/acs.jafc.7b01964
• Publication Date: 2017-07-26T13:39:37Z
• Authors: Xinzhou Yang; Mi Huang; Jie Yang; Jialin Wang; Sijian Zheng; Xinhua Ma; Jinyan Cai; Shihao Deng; Guangwen Shu; Guangzhong Yang
• Keywords: GLUT4; AMP-Activated Protein Kinase; Hyperlipidemia; Troglitazone; Rosiglitazone; Lipogenesis

This study was designed to explore the effects and mechanism of isoliensinine (isolie) from embryos Nelumbo nucifera on type 2 diabetes dyslipidemia in vivo vitro. The vitro showed that isolie increased GLUT4 translocation by 2.5-fold L6 cells. Furthermore, after 4 weeks treatment, biochemical indexes revealed had a positive effect decreasing serum insulin level (42.2 ± 5.10 vs 55.7 6.33 mU/L, P < 0.05) reducing fast blood glucose (9.4 1.5 18.7 2.3 mmol/L, 0.001) body weight (37.8 2.9 46.9 5.4 g, compared with KK-Ay model mice. Isolie treatment led significant increases proteins (∼2.7-fold skeletal muscle ∼2.4-fold WAT) phosphorylated AMP-activated protein kinase (∼1.4-fold muscle, ∼3.1-fold WAT, ∼2.3-fold liver). However, caused decrease lipogenesis expressions PPARγ SREBP-1c, decreased activity ACC increasing phospho-ACC level. Our findings has potential alleviate associated hyperlipidemia Regulation GLUT4, PPARγ, AMPK phosphorylation, phosphorylation is implicated antidiabetic isolie.